SK Biopharmaceuticals Co., Ltd.
326030
Peringkat dalam Saham
#4041
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Harga Saham
$51.31
Kapitalisasi Pasar
$4.02B
Perubahan (1 hari)
-2.62%
Perubahan (1 tahun)
-28.88%
Negara
KR
Perdagangan SK Biopharmaceuticals Co., Ltd. (326030)
Kategori
Healthcare
EPS untuk SK Biopharmaceuticals Co., Ltd. (326030)
EPS per June 2026 TTM: $3.42
Menurut laporan keuangan terbaru dan harga saham SK Biopharmaceuticals Co., Ltd., EPS perusahaan saat ini (TTM) adalah $3.42. Pada akhir 2024, perusahaan memiliki EPS sebesar $2.09 peningkatan dibandingkan EPS tahun 2023 sebesar $-0.32.
Riwayat EPS untuk SK Biopharmaceuticals Co., Ltd. dari 2011 hingga 2026
EPS di akhir setiap tahun
| Tahun | EPS | Mengubah |
|---|---|---|
| 2026 (TTM) | $3.42 | 52.67% |
| 2025 | $2.24 | 7.31% |
| 2024 | $2.09 | -743.06% |
| 2023 | $-0.32 | -77.01% |
| 2022 | $-1.41 | -302.57% |
| 2021 | $0.70 | -121.93% |
| 2020 | $-3.18 | 233.25% |
| 2019 | $-0.95 | -52.18% |
| 2018 | $-1.99 | 8.75% |
| 2017 | $-1.83 | 264.02% |
| 2016 | $-0.50 | 5.40% |
| 2015 | $-0.48 | -30.23% |
| 2014 | $-0.68 | -29.69% |
| 2013 | $-0.97 | 36.72% |
| 2012 | $-0.71 | 69.47% |
| 2011 | $-0.42 | 0.00% |
EPS untuk perusahaan sejenis atau pesaing
| Perusahaan | EPS | Perbedaan EPS | Negara |
|---|---|---|---|
| $17.32 | 406.48% |
US
|
|
| $-7.98 | -333.35% |
US
|
|
| $-5.29 | -254.69% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 711.18% |
NL
|
